The data come from large studies with almost 23,000 participants receiving low, steady doses. The results point to meaningful drops in major cardiovascular events while most side effects were mild and temporary. Because colchicine is inexpensive and widely available, these findings raise an important possibility for global health: an affordable therapy that could narrow gaps in prevention where newer drugs are too costly.
This topic matters for anyone thinking about how to keep aging bodies healthier and how to make prevention fairer across communities. The next steps will probe long-term safety, which patients benefit most, and how this treatment might pair with existing care. Follow the full article to see how a century-old medicine could reshape approaches to heart and brain health and what that means for the future of inclusive, practical prevention.
Colchicine, a cheap and widely used gout drug, may help prevent heart attacks and strokes in people with cardiovascular disease. Trials involving nearly 23,000 patients show meaningful reductions in risk with low doses. Side effects were mostly mild and short-lived. Researchers say this overlooked drug could become an accessible prevention tool pending further study.
